^
    Back
    Association details:
    Biomarker:KEAP1 negative
    Cancer:Melanoma
    Drug Class:PD1 inhibitor +
    CTLA4 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    NPJ Precis Oncol
    Title:

    Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade

    Published date:
    03/02/2023
    Excerpt:
    Notably, KEAP1 expression is elevated in CTCs from CR patients and undetectable in all but one CTC from patients with PD...Thus, loss of KEAP1 expression and associated upregulation of NRF2 signaling within individual melanoma CTCs are associated with poor response to ICB in our CTC cohort.
    DOI:
    10.1038/s41698-023-00362-3